Back to Search
Start Over
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
- Source :
-
Zhonghua zhong liu za zhi [Chinese journal of oncology] [Zhonghua Zhong Liu Za Zhi] 2010 Oct; Vol. 32 (10), pp. 786-90. - Publication Year :
- 2010
-
Abstract
- Objective: To assess the efficacy and safety of bevacizumab plus irinotecan-based regimen for the first line treatment in metastatic colorectal cancer (mCRC) patients, and to investigate the correlation between serum tumor markers including CEA and CA19-9 and response as well as prognosis.<br />Methods: From May 2007 to July 2008, 67 previously untreated mCRC patients received treatment of IFL (n = 25), IFL plus Bevacizumab (n = 20) or FOLFIRI (n = 22). The treatment continued until disease progression or unacceptable toxicity. The data were retrospectively analyzed.<br />Results: All patients were evaluable for response, survival and toxicity analysis. The objective response rate of IFL, IFL plus Bevacizumab or FOLFIRI regimen groups was 16.0% (4/25), 35.0% (7/20) and 18.2% (4/22), respectively (χ(2) = 6.026, P = 0.049). The median progression-free survival (PFS) of IFL plus bevacizumab group was 7.5 months, significantly improved as compared with 3.7 months in the IFL group and 4 months in FOLFIRI group (χ(2) = 11.97, P = 0.003). Of all 67 cases, the one-year survival rate was 47.0%, two-year survival rate was 27.0%, and the median overall survival (OS) was 13.0 months, with no significant difference among the three treatment groups (χ(2) = 3.42, P = 0.18). The serum CEA and CA19-9 levels were decreased after treatment, but with no significant difference among the three groups (P > 0.05). The common toxicity profiles of IFL and FOLFIRI regimens were diarrhea and neutropenia, while the toxicity related to bevacizumab was consistent with that documented in previous literature, such as hypertension, hemorrhage, cardiac toxicity and delayed wound healing.<br />Conclusion: The addition of bevacizumab to irinotecan-based regimen significantly improves the response rate and PFS in first-line treatment for patients with mCRC and its toxicity is well tolerated.
- Subjects :
- Adenocarcinoma blood
Adenocarcinoma secondary
Adenocarcinoma, Mucinous blood
Adenocarcinoma, Mucinous drug therapy
Adenocarcinoma, Mucinous secondary
Adult
Aged
Angiogenesis Inhibitors adverse effects
Angiogenesis Inhibitors therapeutic use
Antibodies, Monoclonal, Humanized adverse effects
Antineoplastic Combined Chemotherapy Protocols adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bevacizumab
CA-19-9 Antigen blood
Camptothecin administration & dosage
Camptothecin therapeutic use
Carcinoembryonic Antigen blood
Colonic Neoplasms blood
Colonic Neoplasms secondary
Diarrhea chemically induced
Disease-Free Survival
Female
Fluorouracil administration & dosage
Fluorouracil therapeutic use
Follow-Up Studies
Humans
Hypertension chemically induced
Irinotecan
Leucovorin therapeutic use
Male
Middle Aged
Neutropenia chemically induced
Rectal Neoplasms blood
Rectal Neoplasms secondary
Remission Induction
Retrospective Studies
Survival Rate
Young Adult
Adenocarcinoma drug therapy
Antibodies, Monoclonal, Humanized therapeutic use
Camptothecin analogs & derivatives
Colonic Neoplasms drug therapy
Rectal Neoplasms drug therapy
Subjects
Details
- Language :
- Chinese
- ISSN :
- 0253-3766
- Volume :
- 32
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- Zhonghua zhong liu za zhi [Chinese journal of oncology]
- Publication Type :
- Academic Journal
- Accession number :
- 21163073